Samuel H. Whiting

1.4k total citations
18 papers, 435 citations indexed

About

Samuel H. Whiting is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Samuel H. Whiting has authored 18 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Cancer Research and 4 papers in Molecular Biology. Recurrent topics in Samuel H. Whiting's work include Pancreatic and Hepatic Oncology Research (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and HIV Research and Treatment (3 papers). Samuel H. Whiting is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and HIV Research and Treatment (3 papers). Samuel H. Whiting collaborates with scholars based in United States, Bulgaria and Canada. Samuel H. Whiting's co-authors include James J. Champoux, Kendall C. Shibuya, Venu G. Pillarisetty, Jonathan G. Sham, Wei Xiong, Seth M. Pollack, Stanley R. Riddell, Terry Katz, Vikas Goel and Floyd E. Fox and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Samuel H. Whiting

18 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samuel H. Whiting United States 12 203 176 79 74 73 18 435
Pankita H. Pandya United States 9 145 0.7× 165 0.9× 143 1.8× 64 0.9× 51 0.7× 20 475
Soji Toda Japan 10 96 0.5× 132 0.8× 146 1.8× 49 0.7× 25 0.3× 52 459
Jayamanna Wickramasinghe United States 11 212 1.0× 391 2.2× 148 1.9× 9 0.1× 76 1.0× 14 648
Cheng-po Hu Taiwan 13 174 0.9× 243 1.4× 108 1.4× 19 0.3× 78 1.1× 18 620
Mónika Ádori Sweden 11 106 0.5× 90 0.5× 254 3.2× 62 0.8× 34 0.5× 28 422
Daniel A. Kuppers United States 10 442 2.2× 159 0.9× 47 0.6× 30 0.4× 58 0.8× 13 610
Angelika Schlamp Germany 7 104 0.5× 149 0.8× 384 4.9× 19 0.3× 30 0.4× 9 482
Debra K. Shivers United States 10 36 0.2× 87 0.5× 179 2.3× 77 1.0× 28 0.4× 11 343
Julia Dietz Germany 17 60 0.3× 171 1.0× 170 2.2× 66 0.9× 42 0.6× 50 776
Carla Pereira Canada 6 50 0.2× 120 0.7× 237 3.0× 74 1.0× 22 0.3× 7 385

Countries citing papers authored by Samuel H. Whiting

Since Specialization
Citations

This map shows the geographic impact of Samuel H. Whiting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel H. Whiting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel H. Whiting more than expected).

Fields of papers citing papers by Samuel H. Whiting

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel H. Whiting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel H. Whiting. The network helps show where Samuel H. Whiting may publish in the future.

Co-authorship network of co-authors of Samuel H. Whiting

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel H. Whiting. A scholar is included among the top collaborators of Samuel H. Whiting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel H. Whiting. Samuel H. Whiting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Tannir, Nizar M., Alice C. Fan, Richard J. Lee, et al.. (2018). Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology. 36(6_suppl). 603–603. 20 indexed citations
2.
Cohn, Allen Lee, Michael A. Morse, Bert H. O’Neil, et al.. (2018). Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. Journal of Immunotherapy. 41(3). 141–150. 32 indexed citations
3.
Tannir, Nizar M., Robert J. Motzer, Neeraj Agarwal, et al.. (2018). CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.. Journal of Clinical Oncology. 36(15_suppl). TPS4601–TPS4601. 17 indexed citations
4.
DeMichele, A., P.N. Munster, Othon Iliopoulos, et al.. (2017). Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC). Cancer Research. 77(4_Supplement). P6–11. 1 indexed citations
5.
Coveler, Andrew L., Venu G. Pillarisetty, Wui‐Jin Koh, et al.. (2014). A phase II study of perioperative therapy for patients with resectable and borderline-resectable pancreatic adenocarcinoma.. Journal of Clinical Oncology. 32(15_suppl). 4120–4120. 3 indexed citations
6.
Shibuya, Kendall C., Vikas Goel, Wei Xiong, et al.. (2014). Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment. PLoS ONE. 9(5). e96565–e96565. 99 indexed citations
7.
Richards, Donald, Peter Muscarella, Tanios Bekaii‐Saab, et al.. (2014). Abstract 5314: A proteomic signature predicts response to a therapeutic vaccine in pancreas cancer; analysis from the GI-4000-02 trial. Cancer Research. 74(19_Supplement). 5314–5314. 2 indexed citations
8.
Nemunaitis, John, et al.. (2014). Tolerability, humoral immune response, and disease control in phase 1 patients receiving ONT-10, a MUC1 liposomal vaccine.. Journal of Clinical Oncology. 32(15_suppl). 3091–3091. 5 indexed citations
9.
McCormick, Kinsey A., et al.. (2014). Long-term survival of patients receiving multimodality neoadjuvant therapy for resectable or borderline resectable pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 32(3_suppl). 309–309. 1 indexed citations
10.
Zhao, Mengxia, Wyatt C. Nelson, Bingchuan Wei, et al.. (2013). New Generation of Ensemble-Decision Aliquot Ranking Based on Simplified Microfluidic Components for Large-Capacity Trapping of Circulating Tumor Cells. Analytical Chemistry. 85(20). 9671–9677. 25 indexed citations
11.
12.
Liu, David, Andrew S. Kennedy, David C. Turner, et al.. (2009). Minimally Invasive Techniques in Management of Hepatic Neuroendocrine Metastatic Disease. American Journal of Clinical Oncology. 32(2). 200–215. 18 indexed citations
13.
LoRusso, Patricia, Michael A. Gordon, Evan Y. Yu, et al.. (2007). A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis. Molecular Cancer Therapeutics. 6. 9 indexed citations
14.
Higano, Celestia S., Samuel H. Whiting, Michael Gordon, et al.. (2007). A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3505–3505. 71 indexed citations
15.
Whiting, Samuel H. & James J. Champoux. (1998). Properties of strand displacement synthesis by moloney murine leukemia virus reverse transcriptase: mechanistic implications. Journal of Molecular Biology. 278(3). 559–577. 42 indexed citations
16.
Schultz, Sharon J., Samuel H. Whiting, & James J. Champoux. (1995). Cleavage Specificities of Moloney Murine Leukemia Virus RNase H Implicated in the Second Strand Transfer During Reverse Transcription. Journal of Biological Chemistry. 270(41). 24135–24145. 20 indexed citations
17.
Whiting, Samuel H. & James J. Champoux. (1994). Strand displacement synthesis capability of Moloney murine leukemia virus reverse transcriptase. Journal of Virology. 68(8). 4747–4758. 43 indexed citations
18.
Whiting, Samuel H., et al.. (1979). Cinnarizine in the treatment of chronic asthma.. British Journal of Clinical Pharmacology. 7(2). 189–195. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pankita H. Pandya Breakdown of academic impact, for papers by Soji Toda Breakdown of academic impact, for papers by Jayamanna Wickramasinghe Breakdown of academic impact, for papers by Cheng-po Hu Breakdown of academic impact, for papers by Mónika Ádori Breakdown of academic impact, for papers by Daniel A. Kuppers Breakdown of academic impact, for papers by Angelika Schlamp Breakdown of academic impact, for papers by Debra K. Shivers Breakdown of academic impact, for papers by Julia Dietz Breakdown of academic impact, for papers by Carla Pereira
Rankless by CCL
2026